Abstract
Topoisomerase II alpha content, topoisomerase II catalytic activity and drug sensitivities to the topoisomerase II inhibitors, doxorubicin and etoposide, were examined in a panel of 14 unselected human lung cancer cell lines in order to determine the relationship between topoisomerase II and drug sensitivities to the topoisomerase II inhibitors. Drug sensitivities were determined using a microculture tetrazolium assay. The topoisomerase II alpha levels were determined by Western blot analysis and the topoisomerase II catalytic activity was determined using a decatenation assay of kinetoplast DNA, using nuclear protein from cells of each cell line. Drug sensitivity tests revealed that small-cell lung cancer (SCLC) cell lines were more sensitive to drugs than non-small-cell lung cancer (NSCLC) cell lines. The relative topoisomerase II alpha levels and relative topoisomerase II catalytic activity from SCLC cell lines (mean +/- SD 0.89 +/- 0.54 and 5.3 +/- 3.4, respectively) were slightly higher than those from NSCLC cell lines (0.78 +/- 0.56 and 4.0 +/- 2.8, respectively), but the differences were not statistically significant, and not sufficient to account for the variation in drug sensitivities. Moreover, no clear association wa...Continue Reading
Citations
Jun 9, 2007·Archivum Immunologiae Et Therapiae Experimentalis·Beata M GruberWaldemar Priebe
Apr 16, 1998·Pharmacology & Therapeutics·M Kolaczkowski, A Goffeau
Jun 18, 2002·The Lancet Oncology·Udo KellnerPierre Rudolph
Jul 18, 2008·Nucleic Acids Research·Kate E ColdwellDon R Phillips
Aug 12, 1999·British Journal of Haematology·V L LockeM W Davey
Oct 4, 2006·Expert Opinion on Drug Metabolism & Toxicology·Aalok NadkarSanjay Awasthi
Sep 7, 2012·PloS One·Yanlin LiMinjie Wei
Aug 29, 2014·PLoS Genetics·Masahiro TerasawaMiki Shinohara
May 4, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S L Holbeck
Dec 30, 2008·Cancer Letters·Alan CossJacintha N O'Sullivan
Aug 25, 2004·The Journal of Pharmacy and Pharmacology·M SawickaW Lewandowski
Oct 8, 2009·Cancer Chemotherapy and Pharmacology·Yoshitsugu HorioYoshitaka Sekido
Oct 10, 1998·Japanese Journal of Cancer Research : Gann·E SyahruddinM Yamakido
Apr 1, 2000·Japanese Journal of Cancer Research : Gann·S HirataK Yajin
Jul 12, 2017·Oncogene·J C SenturkJ J Manfredi
Oct 25, 2020·Cell Communication and Signaling : CCS·Qi DongZhihao Wu
Jan 6, 2010·Critical Reviews in Oncology/hematology·David J Stewart